US Drug Recall Register
Class II · Moderate risk Terminated Initiated Mar 8, 2022 (4 years ago)

NAD+ Nicotinamide Adenine Dinucleotide

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Product found to be Sub Potent or Exceeded reconstitution time

What was recalled

NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Each ML contains: 0.288% Sodium Phosphate Monobasic USP, 0.42% Sodium Phosphate Dibasic USP, 5% Mannitol USP, Sterile Water for Injection USP, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835 NDC: 73198-0083-00

Recalling firm
Olympia Compounding Pharmacy dba Olympia Pharmacy
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0719-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Mannitol recalls

See all
Class II · Moderate risk Terminated

Cardioplegia Solution del Nido Formula

Reason Lack of Assurance of Sterility:Lack of validation data for sanitization cycles

Central Admixture Pharmacy Services, Inc. D-1112-2023
Class II · Moderate risk Terminated

Cardioplegia Solution del Nido Formula

Reason Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Central Admixture Pharmacy Services, Inc. D-0956-2023
Class III · Low risk Terminated

Netspot

Reason Subpotent Drug: low out-of-specification results for Vial 1 assay obtained during stability studies.

Advanced Accelerator Applications USA, Inc. NDC 69488-001-40 D-0747-2022